Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by CERo Therapeutics Holdings, Inc.
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
November 15, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
November 11, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Provides Corporate Update
October 21, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
October 02, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
September 25, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
July 08, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
June 13, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
June 06, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
May 15, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Tickers
CERO
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
March 07, 2024
From
CERo Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
CERO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.